Dry Static Apnoea for Recovery From Acute Laboratory Stress in Trained Breath-Hold Divers

November 16, 2026 updated by: DeAsís-Fernández, Francisco, Universidad Rey Juan Carlos

Dry Static Apnoea as a Stress-Recovery Strategy: Salivary Cortisol and Heart Rate Variability After Acute Laboratory Stress in Trained Breath-Hold Divers. A Randomized Controlled Trial

This exploratory randomized controlled trial will test whether a short session of dry static apnoea (voluntary breath-holding while lying down, out of the water) helps trained breath-hold divers recover faster from a brief, standardized laboratory stressor than resting for the same amount of time.

Twenty-eight licensed breath-hold divers will attend a single afternoon session of about 85 minutes. All participants first complete the Maastricht Acute Stress Test (alternating immersion of one hand in cold water at about 2 °C with mental arithmetic and negative feedback). They are then randomly assigned to one of two 24-minute conditions: four supervised dry static apnoeas at 50% of their personal best (maximum 3 minutes each), or lying at rest while listening to a neutral informative audio. Both groups then rest until 60 minutes after the start of the stressor.

The main outcome is salivary cortisol 60 minutes after the start of the stressor. Heart rate, heart rate variability, blood pressure, state anxiety and perceived stress will also be compared between groups.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

Background. Acute stress activates the hypothalamic-pituitary-adrenal axis, which releases cortisol, and the autonomic nervous system, which raises heart rate and reduces vagal tone. For health, how quickly these responses return to baseline matters as much as their magnitude. Slow, controlled breathing increases vagal modulation and is associated with lower anxiety. Voluntary apnoea shares conscious breathing control and additionally triggers a vagally mediated bradycardia (the diving response), which is also present in dry apnoea. Breath-hold divers often report feeling calmer after training, but this has not been tested with objective markers. To avoid the floor effect of afternoon cortisol, a standardized stressor is applied first and the trial then tests whether apnoea accelerates recovery compared with rest. Trained breath-hold divers are studied because they master the technique and do not find it aversive.

Design. Exploratory, two-arm, parallel-group randomized controlled trial with a blinded outcome assessor. Randomization in blocks of 4, stratified by sex. The outcome assessor is unaware of group allocation; the principal investigator delivers the intervention. Sessions take place in the afternoon (arrival between 15:30 and 17:00) to control for the circadian rhythm of cortisol, at the Faculty of Health Sciences, Alcorcón Campus, Universidad Rey Juan Carlos (Madrid, Spain).

Session (about 85 minutes). Baseline rest and recordings; Maastricht Acute Stress Test (5 minutes of instructions and 10 minutes alternating hand immersion in water at about 2 °C with mental arithmetic aloud and negative feedback); 24-minute intervention; rest until 60 minutes after stressor onset; final debriefing.

Interventions. Experimental group: 4 dry static apnoeas in the supine position at 50% of personal best (maximum 3 minutes), in 5-minute cycles with at least 2 minutes of free breathing between apnoeas, under continuous supervision. Hyperventilation and lung packing are not allowed. Control group: supine rest for the same duration while listening to a neutral informative audio, previously validated with the Self-Assessment Manikin.

Measurements. Four passive-drool saliva samples (S1 at -7, S2 at +22, S3 at +50 and S4 at +60 minutes relative to stressor onset), stored on ice, frozen at -20 °C and analysed in duplicate by ELISA (Demeditec DES6611). R-R intervals and ECG are recorded with a Polar H10 chest strap and analysed with Kubios HRV; blood pressure with an automatic Omron monitor; SpO2 with a finger pulse oximeter. Validated Spanish questionnaires: PSS-14, STAI-Trait, ASI-3 and MAIA-2 (online screening); STAI-6 and a visual analogue scale of stress (four times during the session); Karolinska Sleepiness Scale (end of session). Descriptive and control variables: age, sex, years of practice and personal best; menstrual cycle phase, sleep, caffeine and physical activity on the day of the session.

Statistical analysis. Cortisol will be log-transformed. Primary analysis: ANCOVA of log(S4) with group as factor and log(S1) and log(S2) as covariates. Complementary analysis: linear mixed model (group x time, S1-S4). Autonomic and subjective outcomes will be analysed in the same way, with Holm correction. Sensitivity analyses: stress responders only; adjustment for menstrual cycle phase and sex. Exploratory moderation analyses: trait anxiety, anxiety sensitivity, interoceptive awareness, chronic perceived stress and the cortisol response to the stressor. Effect sizes with 95% confidence intervals will be reported to inform the sample size of a confirmatory trial.

Sample size. As an exploratory trial, no formal power calculation is performed; following the recommendation of at least 12 participants per group for pilot studies (Julious, 2005), 28 participants (14 per group) will be enrolled to allow for losses.

Safety. Apnoeas are performed dry and lying down, which removes the risk of drowning and falls. Heart rate and SpO2 are monitored continuously and the apnoea is stopped if SpO2 falls below 85% or any symptom appears. Participants may remove the hand from the cold water at any time. A written syncope protocol is in place and a defibrillator is available at the faculty.

Study Type

Interventional

Enrollment (Estimated)

28

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Madrid
      • Alcorcón, Madrid, Spain, 28922
        • Universidad Rey Juan Carlos, Faculty of Health Sciences, Alcorcón Campus
        • Contact:
        • Principal Investigator:
          • Francisco de Asís Fernández Martínez, PhD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Age 18 years or older
  • Current breath-hold diving (apnoea) federation licence with insurance
  • Personal best in dry static apnoea of at least 2 minutes

Exclusion Criteria:

  • Cardiovascular, respiratory or endocrine disease, or hypertension
  • Contraindication to cold exposure (e.g., Raynaud's phenomenon)
  • Use of corticosteroids, beta-blockers or psychotropic drugs
  • Smoking
  • Pregnancy
  • Use of hormonal contraceptives
  • Periodontal disease
  • Shift work
  • Previous experience with laboratory stressors

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Dry static apnoea

Participants complete the Maastricht Acute Stress Test and then perform a 24-minute dry static apnoea session, followed by supine rest until 60 minutes after stressor onset.

Four dry static apnoeas in the supine position, each lasting 50% of the participant's personal best (maximum 3 minutes), in 5-minute cycles with at least 2 minutes of free breathing between apnoeas. Hyperventilation and lung packing are not allowed. Continuous supervision by an investigator trained in apnoea and first aid, with heart rate and SpO2 monitoring; the apnoea is stopped if SpO2 falls below 85% or any symptom appears.

Standardized laboratory stressor: 5 minutes of instructions followed by 10 minutes alternating periods of 45-90 seconds with one hand immersed in water at about 2 °C with periods of mental arithmetic aloud with negative feedback. Participants can remove the hand at any time. Debriefing at the end of the session.

Other Names:
  • MAST
Other: Passive rest

Participants complete the Maastricht Acute Stress Test and then rest for 24 minutes listening to a neutral audio (time-matched control), followed by supine rest until 60 minutes after stressor onset.

Standardized laboratory stressor: 5 minutes of instructions followed by 10 minutes alternating periods of 45-90 seconds with one hand immersed in water at about 2 °C with periods of mental arithmetic aloud with negative feedback. Participants can remove the hand at any time. Debriefing at the end of the session.

Other Names:
  • MAST

Supine rest listening through headphones to a neutral informative audio, previously validated as emotionally neutral with the Self-Assessment Manikin. No breathing instructions are given.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Salivary cortisol 60 minutes after stressor onset (S4)
Time Frame: 60 minutes after the start of the stressor (S4), within the single experimental session; samples at 7 minutes before (S1) and 22 minutes after (S2) stressor onset are used as covariates
60 minutes after the start of the stressor (S4), within the single experimental session; samples at 7 minutes before (S1) and 22 minutes after (S2) stressor onset are used as covariates

Secondary Outcome Measures

Outcome Measure
Time Frame
Salivary cortisol across the session
Time Frame: 7 minutes before (S1) and 22 (S2), 50 (S3) and 60 (S4) minutes after stressor onset, within the single experimental session
7 minutes before (S1) and 22 (S2), 50 (S3) and 60 (S4) minutes after stressor onset, within the single experimental session
Heart rate
Time Frame: Baseline rest, stressor, 24-minute intervention period and recovery up to 60 minutes after stressor onset, within the single experimental session
Baseline rest, stressor, 24-minute intervention period and recovery up to 60 minutes after stressor onset, within the single experimental session
Heart rate variability (RMSSD)
Time Frame: Baseline rest, stressor, 24-minute intervention period and recovery up to 60 minutes after stressor onset, within the single experimental session
Baseline rest, stressor, 24-minute intervention period and recovery up to 60 minutes after stressor onset, within the single experimental session
Systolic and diastolic blood pressure
Time Frame: Three measurements during the single experimental session: baseline, after the stressor and at the end of the session (60 minutes after stressor onset)
Three measurements during the single experimental session: baseline, after the stressor and at the end of the session (60 minutes after stressor onset)
State anxiety (STAI-6)
Time Frame: Four time points during the single experimental session: baseline, after the stressor, after the intervention period and at the end of the session
Four time points during the single experimental session: baseline, after the stressor, after the intervention period and at the end of the session
Perceived stress (visual analogue scale)
Time Frame: Four time points during the single experimental session: baseline, after the stressor, after the intervention period and at the end of the session
Four time points during the single experimental session: baseline, after the stressor, after the intervention period and at the end of the session
Minimum peripheral oxygen saturation during apnoeas (apnoea group only)
Time Frame: During each of the 4 apnoeas of the 24-minute intervention period
During each of the 4 apnoeas of the 24-minute intervention period
Minimum heart rate during apnoeas (apnoea group only)
Time Frame: During each of the 4 apnoeas of the 24-minute intervention period
During each of the 4 apnoeas of the 24-minute intervention period

Other Outcome Measures

Outcome Measure
Time Frame
Sleepiness (Karolinska Sleepiness Scale)
Time Frame: End of the single experimental session (60 minutes after stressor onset)
End of the single experimental session (60 minutes after stressor onset)
Number of participants with adverse events
Time Frame: From the start to the end of the single experimental session (about 85 minutes)
From the start to the end of the single experimental session (about 85 minutes)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Francisco de Asís Fernández Martínez, PhD, Universidad Rey Juan Carlos

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

January 11, 2027

Primary Completion (Estimated)

April 30, 2027

Study Completion (Estimated)

May 31, 2027

Study Registration Dates

First Submitted

November 16, 2026

First Submitted That Met QC Criteria

November 16, 2026

First Posted (Actual)

November 20, 2026

Study Record Updates

Last Update Posted (Actual)

November 20, 2026

Last Update Submitted That Met QC Criteria

November 16, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • URJC-APNEA-STRESS-2026
  • 061020267142026 (Other Identifier: Research Ethics Committee, Universidad Rey Juan Carlos)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.